390
Participants
Start Date
December 16, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
May 31, 2025
rhTNK-tPA
rhTNK-tPA (0.25 mg/kg, maximum dose 25mg) is given as a single, intravenous bolus (injection over 5 to 10 seconds) immediately upon randomization. EVT should be performed as soon as possible after rhTNK-tPA administration.
direct EVT
During the study period, NMPA-approved stents are permitted. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.
ACTIVE_NOT_RECRUITING
Beijing Tiantan Hospital, Capital Medical University, Beijing
ACTIVE_NOT_RECRUITING
Eastern Theater General Hospital, Nanjing
ACTIVE_NOT_RECRUITING
Liaocheng Third People's Hospital, Liaocheng
ACTIVE_NOT_RECRUITING
Qingdao Central Hospital, Qingdao
ACTIVE_NOT_RECRUITING
Heze Municipal Hospital, Heze
RECRUITING
Linyi People's Hospital, Linyi
ACTIVE_NOT_RECRUITING
Rizhao People's Hospital, Rizhao
ACTIVE_NOT_RECRUITING
Rizhao Traditional Chinese Medicine Hospital, Rizhao
ACTIVE_NOT_RECRUITING
Linfen Central Hospital, Linfen
ACTIVE_NOT_RECRUITING
First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an
Linyi People's Hospital
OTHER
Beijing Tiantan Hospital
OTHER